All Articles

With $911M in the bank, Relay Therapeutics is aggressively advancing its precision drug zovegalisib, targeting both breast cancer and rare vascular anomalies.

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.

Kodiak AI posts strong Q2 growth and unveils its Gen7 platform, accelerating its push for driverless long-haul. But can revenue outpace a steep cash burn?

NATR's Q2 results show a firm investing heavily in its digital future, with soaring e-commerce sales and subscription growth offsetting currency and China woes.

Artiva Biotherapeutics secures FDA fast-track status for its novel NK cell therapy, AlloNK. This could revolutionize autoimmune care for millions.

The nation's only public parking firm faces an insider offer, placing a special committee at the center of a high-stakes test for shareholder value.

With late-stage trials underway and a cash runway into 2030, Trevi Therapeutics is accelerating its mission. But what does this mean for millions of unseen sufferers?

While Q2 results show a net loss, Bridger Aerospace secures record contracts and expands its tech, signaling a strategic shift for a new era of wildfire.

A new press release touts 'simplicity' as the future of digital entertainment. But for online gaming platform Mr Win77, are the real complexities hidden?

With nearly $1B in cash and a shrinking net loss, Janux is pushing its advanced prostate cancer drugs while its novel autoimmune therapy nears a key data reveal.

Outset Medical's Q2 results reveal a pivotal moment: a major HCA deal and stronger margins point to a new phase of sustainable growth in the dialysis market.

Clipper Realty's latest earnings reveal a stark divide. Record-breaking residential rents are being overshadowed by a major commercial property default.

Doximity's Q1 results reveal a company at a crossroads, sacrificing near-term profits for AI dominance. Engagement is soaring, but financials are strained.

Stunning 120% revenue growth validates Senseonics' shift to in-house sales, but soaring costs and a widening net loss raise critical questions about its path to profitability.

With a Q3 FDA submission for its novel epilepsy drug azetukalner imminent, Xenon leverages a massive cash runway to expand into neuropsychiatry and pain.

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.

A biotech firm has uncovered a self-perpetuating cycle that drives Alzheimer's from within the cell's mitochondria, and they've developed a drug to break it.

The strategic acquisition of The Mobility House North America by PowerFlex signals a major market consolidation, creating an end-to-end fleet solution powerhouse.

A Texas-based program offers a government-funded, no-cost path to six-figure IT jobs, providing a powerful new blueprint for closing the skills gap.

The iconic Canadian jeweler is delisting from the NYSE American. We dig into the financial pressures and strategic calculus behind this pivotal move.